GlassScriptPhysician profile
Eleonora Rozmarin
NPI 1568906337
$7,809.52
in general payments reported to CMS, 2019-2025
38 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,975 · 2022: $1,642 · 2023: $1,536 · 2024: $1,534 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,008 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,007.87 |
| Education | $184.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,348.98 | 2021-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $772.83 | 2021-2025 | |
| Abbvie INC. | $680.04 | 2021-2025 | |
| Novo Nordisk INC | $636.94 | 2021-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $578.30 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.93 | 2021-2025 | Jardiance |
| Oyster Point Pharma, INC. | $326.30 | 2023-2024 | Tyrvaya |
| Bayer Healthcare Pharmaceuticals INC. | $274.78 | 2021-2023 | |
| Opko Pharmaceuticals, LLC | $263.37 | 2021-2025 | Rayaldee |
| Lilly USA, LLC | $222.27 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $158.89 | 2022-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $156.72 | 2021-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $155.01 | 2021-2022 | |
| Medtronic, INC. | $152.20 | 2024 | Symplicity G3 |
| Aimmune Therapeutics, INC. | $139.58 | 2024-2025 | Zenpep |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleonora Rozmarin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.